The purpose of this amendment is to clarify language for the targeted SAE reporting, add language referencing stopping guidance in the DMC charter, and correct omissions from the original protocol. In the inclusion section, wording was changed to accommodate countries where age of adulthood is not 18 years of age. The target population was clarified to address NSTEMI with cardiac biomarkers to distinguish from unstable angina. Study was originally meant to allow patients who had balloon angioplasty, either with or without a stent being placed. Removing the word "with a stent" allows balloon angioplasty without stent. Additional language on unstable angina entry also added for clarification of the population. In addition, other revisions and/or clarifications are listed below within the synopsis and the protocol body. 1. Addition of word “and” after ACS in multiple places to clarify the population. 2. Replaced word antiplatelet with anticoagulant in hypothesis 3. In study figure 3.1.1 clarified exclusion box for CABG 4. Corrected exclusion criteria typo for serum creatinine from 133 micromol/L to 221 micromol/L 5. Deleted duplicate text for WOCBP who are breastfeeding. 6. Deleted Aspirin Placebo from Adverse drug reactions. 7. Added additional subcriteria under “other criteria”. 8. Clarified Prohibited/restricted treatments paragraph 9. Corrected greater than and less than signs 10. Asterisk added for Visits 1-3 in Short Term Procedure Outline 11. Clarified SAE reporting 12. Added paragraph to DMC 13. Clarified wording for Drug Study Records. 14. Added 2 abbreviation to terms table 15. Corrected any typographical errors. Removing the version number from of the Investigator Brochure

The purpose of amendment 02 is to clarify the hypothesis, objectives and patient population in regard to patients who have non-valvular atrial fibrillation and acute coronary syndrome and/or PCI by adding the word “and” in front of “PCI” throughout the protocol, editing the study schematic, as well as to add clarifying language to the targeted SAE reporting section. Table 4-1 was updated to include BMS study medication that will be supplied in some countries where local sourcing is not an option. In addition sections 4.3, 4.8, 4.9, and 9.2.2 were updated based on the mandatory language in the revised protocol model document.

The purpose of Amendment 05 is to reword inconsistent language in the current protocol to clarify the patient eligibility criteria, add an efficacy composite endpoint of all-cause death/all-cause re-hospitalization and to correct typographical errors. In addition, Amendment 05 lists some of the data not specified in the protocol but included in the electronic case report form; this data is planned for potential secondary publications. Medical Monitor Address Change

Amendment 07 - (1) Describes the use of hierarchical statistical testing to analyze the data for apixaban vs VKA and aspirin vs aspirin placebo; (2) Notes the change in the Medical Monitor and his contact information. Change in Medical Monitor Contact information. Date corrected on title page of protocol.